I-MAB
IMAB
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
220
I-MAB News & Analysis
stocks
10 of the cheapest US stocks of 2022
One silver lining of the bear market is half the US stocks followed by Morningstar analysts are now undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.90 | 57.90 | -0.68% |
| CAC 40 | 8,111.78 | 87.93 | -1.07% |
| DAX 40 | 22,749.72 | 397.30 | -1.72% |
| Dow JONES (US) | 43,191.24 | 649.67 | -1.48% |
| FTSE 100 | 8,844.95 | 26.36 | -0.30% |
| HKSE | 22,941.77 | 64.50 | -0.28% |
| NASDAQ | 18,350.19 | 497.09 | -2.64% |
| Nikkei 225 | 37,331.18 | 454.29 | -1.20% |
| NZX 50 Index | 12,469.71 | 80.34 | -0.64% |
| S&P 500 | 5,849.72 | 104.78 | -1.76% |
| S&P/ASX 200 | 8,198.10 | 47.60 | -0.58% |
| SSE Composite Index | 3,324.21 | 7.28 | 0.22% |